AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)CLICK HERE TO GET THE FOX NEWS APPThe drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.Recommendations made by the human medicines committee will have to be formally approved by the European Commission.
Source link
भारत और बहरीन ने रक्षा और सुरक्षा संबंधों को मजबूत किया, और महत्वपूर्ण व्यापार और निवेश समझौतों की ओर कदम बढ़ाया
भारत और बहरीन के बीच निवेश और आर्थिक सहयोग बढ़ाने के लिए वार्ता जारी है। विदेश मंत्री एस…
